CS5001

CS5001 is a clinical-stage antibody-drug conjugate (ADC) targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), an oncofetal protein overexpressed in a broad spectrum of solid tumors and hematological malignancies but largely absent from normal adult tissues. The drug consists of a human anti-ROR1 IgG1 monoclonal antibody site-specifically conjugated to a pyrrolobenzodiazepine (PBD) dimer prodrug via a proprietary lysosomal cleavable β-glucuronide linker. Upon reaching the tumor, the linker is cleaved, releasing the PBD toxin that induces lethal DNA cross-links in cancer cells. This design aims to maximize tumor-specific cytotoxicity while minimizing systemic toxicity associated with traditional PBD payloads. CS5001 has demonstrated complete tumor suppression in preclinical models and encouraging safety and anti-tumor activity in early-phase clinical trials for advanced solid tumors and B-cell lymphomas[3][4][5][6][7].

Other names

ABL Bio-ROR1-ADC